Galderma
Galderma is a major aesthetics company in the botulinum toxin market, but its role differs by product. Dysport is an Ipsen-origin abobotulinumtoxinA product; Galderma commercializes Dysport for aesthetic use in licensed territories. Relfydess is different: it is Galderma’s relabotulinumtoxinA product, approved in international markets but not FDA approved in the United States.
Ipsen remains central to Dysport’s product origin and therapeutic franchise, while Galderma holds significant aesthetic commercialization rights. Relfydess is a separate Galderma-developed product with its own formulation, approvals, and regulatory path.
Quick Answers
Section titled “Quick Answers”| Question | Short answer |
|---|---|
| Is Galderma a botulinum toxin company? | Yes, in market-structure terms. Galderma is linked to botulinum toxin through Dysport aesthetic commercialization and its own relabotulinumtoxinA product, Relfydess. |
| Who makes Dysport? | Dysport belongs to the Ipsen-origin abobotulinumtoxinA product family. Ipsen manufactures and supplies the Dysport family, while Galderma commercializes aesthetic Dysport in licensed territories. |
| Who owns Dysport? | Dysport rights are not a single global ownership answer. Ipsen remains central to the Dysport product family, and Galderma holds important aesthetic commercialization rights in licensed markets. |
| Does Galderma make Dysport? | Ipsen manufactures and supplies Dysport; Galderma commercializes Dysport for aesthetic use in licensed territories. |
| What is Relfydess? | Relfydess is Galderma’s brand name for relabotulinumtoxinA in approved international markets. |
| Is Relfydess FDA approved? | No. Following a Complete Response Letter, Galderma said on October 22, 2026 that it targets resubmission in the first quarter of 2027, subject to further regulatory feedback. |
| Does L’Oréal own Galderma? | L’Oréal holds a 20% minority stake following a transaction completed in February 2026. Galderma remains a separately listed company. (Galderma full-year results 🔗) |
Reference Card
Section titled “Reference Card”| Field | Reference point |
|---|---|
| Company | Galderma Group AG (Galderma investor update 🔗) |
| Base | Switzerland; group headquarters in Zug (Galderma contact information 🔗) |
| Website | galderma.com 🔗 |
| Public status | SIX Swiss Exchange-listed; ticker GALD (Galderma investor update 🔗) |
| Botulinum toxin role | Aesthetic commercialization partner for Dysport-family products in licensed territories and developer of relabotulinumtoxinA |
| Dysport relationship | Galderma commercializes Dysport / Azzalure and Alluzience for aesthetic use in licensed markets; Ipsen remains the manufacturer and supplier |
| Galderma-developed toxin | RelabotulinumtoxinA, marketed as Relfydess in approved international markets |
| Relfydess manufacturing | Galderma’s Aesthetic Center of Excellence in Uppsala, Sweden (Galderma China approval announcement 🔗) |
Galderma’s wider business spans Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Its toxin portfolio sits within Injectable Aesthetics alongside fillers and biostimulators. (Galderma 2025 annual report 🔗)
Ownership And Governance
Section titled “Ownership And Governance”L’Oréal increased its stake in Galderma from 10% to 20%, with the additional investment closing in February 2026. The holding is a minority equity investment; Galderma continues to trade separately on the SIX Swiss Exchange. (Galderma 2025 results and shareholder update 🔗)
On November 2, 2026, Galderma announced that CFO Luigi La Corte had decided to leave but would continue in the role during the transition. The announcement did not name a successor or set a departure date. It also proposed electing Rosalind Brewer and Petra Rumpf to the board at an extraordinary general meeting scheduled for December 3, 2026. These were proposed appointments, not completed elections. (Galderma board and CFO transition announcement 🔗)
Related People
Section titled “Related People”| Person | Why the relationship matters |
|---|---|
| Flemming Ørnskov | Galderma’s Chief Executive Officer, linking corporate strategy to its licensed and internally developed toxin portfolio (October 2026 company announcement 🔗). |
Dysport Manufacturer, Owner, and Ipsen Relationship
Section titled “Dysport Manufacturer, Owner, and Ipsen Relationship”Ipsen manufactures and supplies Dysport, Azzalure, and Alluzience to Galderma, which commercializes them for aesthetic use in licensed territories. Galderma pays royalties to Ipsen under these arrangements. Dysport manufacturer questions therefore point first to Ipsen; Galderma’s role is aesthetic commercialization. (Ipsen 2025 Universal Registration Document, partnership disclosures 🔗)
Dysport ownership questions are more precise when separated into product origin, manufacturing, regulatory labels, and commercialization rights. The relationship is indication- and territory-specific. It does not make Galderma the universal owner or manufacturer of every Dysport presentation, and it does not make aesthetic and therapeutic labels interchangeable.
| Product relationship | Galderma role | Important limit |
|---|---|---|
| Dysport / Azzalure / Alluzience | Licensed aesthetic commercialization in relevant territories | Product origin, manufacturing, labels, and therapeutic context remain tied to Ipsen and local approvals. |
| Relfydess / relabotulinumtoxinA | Galderma-developed botulinum toxin type A product | International approval does not create U.S. approval, unit equivalence, or interchangeability with other toxins. |
Relfydess also has territory-specific contractual rights. Ipsen’s 2025 Universal Registration Document describes an agreement covering Dysport-licensed territories, including specified Asia-Pacific and Latin American markets under which Ipsen holds intellectual-property rights and the marketing-authorization-holder role for Relfydess, while Galderma has exclusive aesthetic manufacturing and commercialization rights and pays royalties to Ipsen. Galderma’s development and manufacturing role therefore does not imply that it holds every legal or regulatory right worldwide. (Ipsen partnership disclosures 🔗)
In January 2026, Galderma reported that an arbitral tribunal confirmed termination of the companies’ 2014 early-stage neuromodulator R&D partnership. It said this did not affect commercialization of its existing portfolio. (Galderma arbitration update, January 21, 2026 🔗)
Separate arbitration filings made on September 29, 2026 concern rights and obligations involving Ipsen’s Long-Acting NeuroToxin clinical program (LANTIC). Galderma says those proceedings do not concern Dysport/Azzalure, Alluzience, or Relfydess. (Galderma October trading update 🔗)
Relfydess Development And International Expansion
Section titled “Relfydess Development And International Expansion”Galderma developed relabotulinumtoxinA internally and manufactures Relfydess at its Aesthetic Center of Excellence in Uppsala, Sweden. (Galderma development and manufacturing announcement 🔗) Relfydess is a ready-to-use liquid botulinum toxin type A product requiring no reconstitution; its potency units are specific to the product and are not interchangeable with other botulinum toxin preparations. (Medsafe Relfydess data sheet 🔗)
Galderma reported 37 market approvals in its October 22, 2026 trading update. That total describes regulatory approvals, not a count of commercial launches. (Galderma international regulatory update 🔗)
On October 23, 2026, Galderma announced Chinese National Medical Products Administration (NMPA) approval for the temporary improvement of moderate-to-severe glabellar lines, or frown lines, in adults. The company expects a commercial launch in China in the second half of 2027. Approval and launch are separate milestones; this announcement does not establish that the product is already commercially available in China. (Galderma China approval and launch plan 🔗)
Relfydess FDA Status: Not U.S. Approved
Section titled “Relfydess FDA Status: Not U.S. Approved”Relfydess is not FDA approved in the United States. Its Biologics License Application (BLA) is the application FDA reviews before deciding whether to license the product. The sequence distinguishes review acceptance, a Complete Response Letter (CRL), and a planned resubmission:
| Milestone | Meaning |
|---|---|
| February 2, 2026: Galderma announced FDA acceptance of a BLA resubmission | The application for adult glabellar and lateral canthal lines entered review; acceptance was not approval. (Galderma FDA acceptance announcement 🔗) |
| July 1, 2026: Galderma announced a CRL | The company attributed FDA’s comments to manufacturing-site inspection observations and analytical-method optimization. Its later October update dates receipt of the CRL to June 2026. (Galderma CRL announcement 🔗) |
| October 22, 2026: Galderma set a first-quarter 2027 resubmission target | The target is subject to further regulatory feedback. A planned filing does not establish acceptance or approval. (Galderma U.S. regulatory update 🔗) |
The manufacturing and analytical issues above are Galderma’s description of FDA feedback. International authorizations remain separate from this U.S. application; local approvals determine each market’s approved indications and conditions of use.
The U.S. botulinum toxin regulatory status page keeps this non-approved BLA stage separate from the FDA approval timeline and current-label indication matrix.
Commercial Scale And Portfolio Expansion
Section titled “Commercial Scale And Portfolio Expansion”For the first nine months of 2026, Galderma reported group net sales of USD 4.765 billion, including USD 1.259 billion in Neuromodulators, up 16.9% year-on-year at constant currency, which removes exchange-rate movements from the growth comparison. The Neuromodulators figure covers the portfolio rather than Relfydess alone; the company described continued Dysport growth and Relfydess launch progress in Europe and Asia Pacific. (Galderma nine-month trading update 🔗)
On October 14, 2026, Galderma announced an agreement to acquire 100% of ZO Skin Health for an enterprise value of USD 1.5 billion. The proposed acquisition expands Dermatological Skincare rather than adding another toxin product. Closing was expected in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and other customary conditions; the agreement announcement does not establish completed ownership. (Galderma ZO Skin Health acquisition agreement 🔗)
Market Interpretation
Section titled “Market Interpretation”Galderma connects an established licensed franchise and a newer internally developed product. Its licensed Dysport business and internally developed Relfydess business have different manufacturing and regulatory histories. Keeping those roles separate prevents Dysport history from being attributed to Relfydess and prevents Relfydess regulatory status from being transferred to Dysport.

